Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Rallybio Q3 2026 Results: Net Loss of $2.73M

Rallybio Corp has announced a proposed merger with Avenzo Therapeutics and continues to report significant losses as a pre-revenue clinical-stage biotechnology company. The company is heavily dependent on the development of its lead candidate, RLYB116, and expects to require substantial additional capital to fund future operations and clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.2
Profit before tax-2.616.0
Net income-2.716.0
EPS (diluted, $ a share)$-0.48$2.84

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: RLYB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Rallybio Corp: key numbers

Share price
$15.43Close, Nov 16
Market cap
$83M
Shares outstanding
5.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Rallybio Corp

All →
4:41 PM ET 8-K
M&A Deal

Rallybio M&A Deal with Avenzo Therapeutics, Inc.

Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.

Counterparty
Avenzo Therapeutics, Inc.
5:21 PM ET 8-K
Reverse Stock Split

Rallybio Reverse Stock Split

Rallybio announced a 1-for-2 reverse stock split effective November 20, 2026, reducing outstanding shares from 5.6 million to 2.8 million. The split is being executed in connection with its pending merger with Avenzo Therapeutics, Inc., after which the combined company will trade under the symbol AVZO. The final ratio was mutually determined by both companies following shareholder approval at the November 4, 2026, annual meeting.

Counterparty
Avenzo Therapeutics, Inc.
5:27 PM ET 8-K
M&A Deal

Rallybio M&A Deal with Avenzo Therapeutics, Inc.

Rallybio Corporation has postponed the closing of its previously announced merger with Avenzo Therapeutics, Inc., which was originally expected to close on November 6, 2026. The delay is due to unsatisfied conditions related to the listing of the company's shares following the transaction. Consequently, the company has also delayed the funding and payment of its previously announced cash distribution to shareholders.

Counterparty
Avenzo Therapeutics, Inc.
4:59 PM ET 8-K
Shareholder Meeting

Rallybio Shareholder Meeting

Rallybio Corporation held its 2026 Annual Meeting of Stockholders where shareholders approved the 2026 Equity Incentive Plan. The plan, which becomes effective upon the completion of the company's merger with Avenzo Therapeutics, initially reserves 18% of the combined company's outstanding common stock for issuance to employees and directors.

4:53 PM ET 8-K
M&A Deal

Rallybio Signs $82.7M M&A Deal with Avenzo Therapeutics, Inc.

Rallybio Corporation provided a status update on its pending merger with Avenzo Therapeutics, declaring a special cash distribution of approximately $82.7 million ($13.56 per share) to stockholders. The distribution is based on the company's estimated net cash exceeding zero prior to the merger closing and is scheduled for payment on November 13, 2026.

Value
$82.7M
Counterparty
Avenzo Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.